Background: Prostate cancer is a major health problem throughout the developed world. Tumor grade is one of the most important prognostic factors of prostate cancer. At present, adequate prognostic markers for prostate cancer progression are still lacking, in spite of intensive investigation. Accordingly, we will study the role of immunohistochemical (IHC) .expression of p53 and Ki67 as a prognostic factor in carcinoma prostate and correlate their expression with Gleason‘s grade. Method : Prostate specimens collected at Deptt. of Pathology, RIMS, Ranchi from July,2017 to October,2018 will be studied prospectively.Prostate fragments will be fixed in 10% formalin, paraffin– embedded, sectioned and standard H and E stained sections will be studied under light microscope and classified into benign and malignant lesions. Carcinoma cases were histologically graded according to Gleason‘s grading system, and Gleason‘s score was noted (well differentiated 2–4, Moderately differentiated 5–7, poorly differentiated 8–10). Result: A total 50 (100%) study participants were included in the study. The age of the study participants varied between 60 years to 83 years with mean (SD) of 70 (±5.08) years. The median age was 70.5 years. Histopathological diagnosis of the study participants were– Benign prostatic hypertrophy –4(8%), Malignant prostate lesion– 43(86%), Basal cell hyperplasia –1(2%), Adenomatous hyperplasia–1(2%) and atrophy of prostate – 1(2%). The tumors were divided into five groups regarding the percentage of Ki–67 positive cells. Cases in which the percentage of stained cells was ≤2% were considered negative. Cases with Ki–67 index of ≤25% were considered 1+, 26–50% as 2+, 51–75% as 3+ and 76–100% as 4+. Immunohistochemical staining of p53 was done and level of p53 reactivity was 0 – 7(14%), 1– 13(26%), 2–15(30%) and3– 15(30%) respectively. Conclusion : From the present study, it will be concluded that frequency of expression of both p53, a tumor suppressor protein, and Ki–67, a cell proliferation marker is significantly up–regulated in malignant lesions as compared to benign lesions.